Using blood microRNAs to detect pancreatic cancer early
Use of Circulating MicroRNAs for Early Detection and Risk Assessment for Pancreatic Cancer
This study is looking at tiny molecules in your blood called microRNAs to see if they can help find pancreatic cancer earlier, and it's for anyone who wants to understand how we can better spot this disease before it becomes serious.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10541824 on NIH RePORTER |
What this research studies
This research focuses on the early detection of pancreatic cancer by analyzing microRNAs (miRNAs) found in blood samples. These miRNAs play a crucial role in cancer development and progression. The study aims to validate previously identified diagnostic indices and improve their accuracy in distinguishing pancreatic cancer patients from healthy individuals and those with chronic pancreatitis. By measuring specific miRNAs in pre-diagnostic plasma samples, the research seeks to identify the most effective time frame for early detection.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for pancreatic cancer, such as those with a family history of the disease or specific genetic predispositions.
Not a fit: Patients who are already diagnosed with advanced pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis of pancreatic cancer, significantly improving patient outcomes and survival rates.
How similar studies have performed: Previous studies have shown promising results in using blood-based miRNA diagnostics for cancer detection, indicating potential for success in this approach.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Shu, Xiao-Ou — Vanderbilt University Medical Center
- Study coordinator: Shu, Xiao-Ou
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.